Evidence map›Paper›PMID 39219588›Full record

ArticleGlobal health & medicine2024

Prospective therapeutic studies of disseminated extranodal large B-cell lymphoma including intravascular large B-cell lymphoma.

Tomoyuki Sakai, Yusuke Ueda, Hiroto Yanagisawa, Kotaro Arita, Haruka Iwao, Kazunori Yamada, Shuichi Mizuta, Hiroshi Kawabata, Toshihiro Fukushima, Katsunori Tai and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Global health & medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Tomoyuki SakaiDepartment of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan.
Yusuke UedaDepartment of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan.
Hiroto YanagisawaDepartment of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan.
Kotaro AritaDepartment of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan.
Haruka IwaoDepartment of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan.
Kazunori YamadaDepartment of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan.
Shuichi MizutaDepartment of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan.
Hiroshi KawabataDepartment of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan.
Toshihiro FukushimaDepartment of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan.
Katsunori TaiDepartment of Hematology and Oncology, University of Fukui Hospital, Fukui, Japan.
Shinji KishiDepartment of Hematology and Oncology, University of Fukui Hospital, Fukui, Japan.
Koji MorinagaDepartment of Hematology and Oncology, Fukui Prefectural Hospital, Fukui, Japan.
Jun MurakamiClinical Laboratory, Transfusion Medicine and Cell therapy, Toyama University Hospital, Toyama, Japan.
Hiroyuki TakamatsuDepartment of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, Japan.
Yasushi TerasakiDivision of Hematology, Toyama City Hospital, Toyama, Japan.
Nobuyuki YoshioNational Hospital Organization Kanazawa Medical Center, Ishikawa, Japan.
Yukio KondoToyama Prefectural Central Hospital, Toyama, Japan.
Hirokazu OkumuraToyama Prefectural Central Hospital, Toyama, Japan.
Sadaya MatanoTonami General Hospital, Toyama, Japan.
Masaki YamaguchiIshikawa Prefectural Central Hospital, Ishikawa, Japan.
Hiroshi TsutaniDepartment of Hematology and Oncology, National Hospital Organization Awara Hospital, Fukui, Japan.
Yasufumi MasakiDepartment of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to establish a standard treatment for disseminated extranodal large B-cell lymphoma, including intravascular large B-cell lymphoma (DEN-LBCL/IVL), and to validate the clinical diagnostic criteria we proposed. Between 2006 and 2016, 22 patients were enrolled in a clinical trial conducted by the Hokuriku Hematology Oncology Study Group. The first cycle of chemotherapy consisted of dose-reduced cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) with delayed administration of rituximab. From the second to the sixth cycle, patients received conventional rituximab and CHOP therapy. The primary endpoint was overall survival (OS), while the secondary endpoints included the complete response (CR) rate and time to treatment failure (TTF). The results showed a CR rate of 73%, a median OS of 65 months, and a median TTF of 45 months. These findings indicate that patients with DEN-LBCL/IVL were effectively treated with our new chemoimmunotherapy regimen. Our clinical diagnostic criteria are useful for identifying patients who require early intervention.

Indexed as

clinical diagnostic criteriaintravascular large B-cell lymphomarandom skin biopsyR-CHOP

Identifiers

PMID39219588
PMCPMC11350362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.